Objective:

To evaluate the impact of treatment intensity on outcomes for transplant-ineligible patients with multiple myeloma (MM), emphasizing its significance in the context of evolving therapies.

Key Findings:

• Quadruplet therapy (Isa-VRd) demonstrated a 60-month progression-free survival (PFS) of 63.2% compared to 45.2% with VRd alone, indicating a significant improvement in treatment efficacy.
• Sustained minimal residual disease (MRD) negativity for 12 months was higher in the quadruplet therapy group, suggesting better long-term outcomes.
• The introduction of novel therapies has significantly improved overall survival from approximately 3 years to more than 8 to 10 years, highlighting the transformative impact of these treatments.

Interpretation:

Intensifying treatment from doublet to quadruplet regimens has led to improved outcomes for transplant-ineligible MM patients, underscoring the critical need to balance efficacy with tolerability, especially in an aging population.

Limitations:

• The trials had differing enrollment criteria and patient populations, which may affect generalizability to the broader MM population.
• Exclusion criteria varied, potentially limiting the applicability of findings to broader patient demographics, particularly older patients with comorbidities.

Conclusion:

Quadruplet therapy represents a significant advancement in the treatment of transplant-ineligible patients with MM, offering improved efficacy while addressing the specific needs of an aging patient population.